Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CARISMA TherapeuticsCARM EV-to-EBITDA is -0.16 as of Aug. 17, 2026. The stock has 3 warning signs investors should review. Among 401 Biotechnology companies, CARISMA Therapeutics ranks better than 98.25% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CARISMA Therapeutics's enterprise value is $-1.92 Mil.
CARISMA Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $12.18 Mil. Therefore, CARISMA Therapeutics's EV-to-EBITDA for today is -0.16.
The historical rank and industry rank for CARISMA Therapeutics's EV-to-EBITDA or its related term are showing as below:
CARM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.6 Med: -0.14 Max: 1.42
Current: -0.16
During the past 5 years, the highest EV-to-EBITDA of CARISMA Therapeutics was 1.42. The lowest was -3.60. And the median was -0.14.
CARM's EV-to-EBITDA is ranked better than 98.25% of 401
companies
in the Biotechnology industry
Industry Median: 13.8
vs CARM: -0.16
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CARISMA Therapeutics's PE Ratio (TTM) for today is calculated as:
CARISMA Therapeutics's share price for today is $0.0022.
CARISMA Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CARISMA Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CARISMA Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARISMA Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's EV-to-EBITDA falls into.
CARISMA Therapeutics's current Enterprise Value is $-1.92 Mil.
CARISMA Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics (CARM) has a EV-to-EBITDA of -0.16 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CARISMA Therapeutics. According to the industry distribution chart, CARISMA Therapeutics ranks #7 out of 401 companies in the Biotechnology industry, placing it in the top 1.7%.
Is CARISMA Therapeutics' EV-to-EBITDA too high?
CARISMA Therapeutics' current EV-to-EBITDA is -0.16. Based on the distribution chart, CARISMA Therapeutics ranks #7 out of 401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CARISMA Therapeutics' EV-to-EBITDA compare to SIGY and CNBX?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #7 out of 401 companies for EV-to-EBITDA. This places CARISMA Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.80, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CARISMA Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARISMA Therapeutics's current EV-to-EBITDA is -0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.00 — trading 99.9% below its estimated fair value. The current EV-to-EBITDA is -0.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current EV-to-EBITDA is -0.16 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CARM has been successfully added to your 
